What Are the Long-Term Side Effects of Citalopram?

Long-term use of citalopram, one of the most widely prescribed SSRIs, carries a side-effect profile that looks meaningfully different from what you experience in the first few weeks. Early side effects like nausea and jitteriness tend to fade, but other problems can emerge or deepen with months and years of use. In a large survey of people who had taken antidepressants for three to fifteen years, roughly nine in ten said the medication improved their depression, yet the majority also reported troubling effects: emotional numbness, sexual problems, weight gain, and difficulty stopping the drug.

Emotional Blunting

One of the most consistently reported long-term complaints is a flattened emotional range, sometimes called emotional blunting. People describe it as feeling less sadness but also less joy, less excitement, and less empathy. In the New Zealand survey of long-term antidepressant users, about two-thirds reported feeling emotionally numb.¹ A review of SSRI side effects found that emotional blunting is the long-term complaint best supported by converging data across studies, more so than cognitive changes or other commonly discussed effects.²

The blunting seems to be a downstream consequence of dampening serotonin-driven emotional signaling. Animal research shows that chronic citalopram reduces baseline noradrenaline in the prefrontal cortex and blunts the dopamine surge that normally accompanies stress or arousal.³ In human terms, that translates to a narrower emotional bandwidth. Some people find the trade-off worthwhile. Others describe it as losing part of themselves. If you recognize this pattern, it is worth raising with your prescriber, because adjusting the dose or switching to a different medication can sometimes restore the emotional range without losing the antidepressant benefit.

Weight Gain

Citalopram is often described as “weight-neutral” in the short term, and early trials did not flag major weight changes. But research into chronic SSRI use tells a different story. Studies lasting a year or more show that SSRIs, including citalopram and paroxetine, are associated with meaningful weight gain over time.⁴ In the long-term user survey, about two-thirds of participants listed weight gain as an adverse effect.⁵

The mechanism involves changes to appetite-regulating pathways in the brain. With prolonged serotonin transporter blockade, certain serotonin receptors in the hypothalamus gradually downregulate, which reduces the activity of signals that tell you to stop eating. The result is a slow, steady increase in food intake that patients often struggle to counteract through diet and exercise alone. This side effect matters because it can undermine motivation to stay on the drug and because the metabolic consequences of the added weight can compound over years.

Sexual Dysfunction and What Happens After Stopping

Sexual side effects are among the most common reasons people want to quit citalopram. In the long-term user survey, nearly three-quarters of respondents reported sexual problems.⁶ These include reduced desire, difficulty reaching orgasm, and in men, erectile problems. Most clinicians expect these effects to resolve after the drug is stopped. For most people, they do. But a subset of patients does not recover normal sexual function even months or years after discontinuation.

This condition, known as post-SSRI sexual dysfunction (PSSD), is characterized by genital numbness, weak or pleasureless orgasm, loss of libido, and erectile dysfunction.⁷ It remains poorly understood and difficult to study because no one has yet pinned down a reliable way to measure how many people are affected. One estimate put the risk at roughly 1 in 216 patients treated with serotonergic antidepressants.⁸ A 2024 review noted that significant barriers remain to quantifying incidence, in part because the condition was only formally recognized by drug regulators relatively recently and clinicians often attribute persistent symptoms to depression itself.⁹ PSSD is rare enough that most people taking citalopram will not develop it, but the possibility of lasting sexual changes is worth knowing about before committing to years of treatment.

Bone Health and Fracture Risk

Bone cells carry serotonin transporters, the same molecular target that citalopram blocks in the brain. Long-term blockade of these transporters in bone tissue appears to weaken bones over time. Research has found that current SSRI use can roughly double the risk of fracture compared to non-use, even after accounting for depression itself, falls, and bone density.¹⁰ A large Canadian population study reported that SSRI or SNRI use was associated with about a 70 percent higher risk of fragility fracture after adjusting for multiple risk factors, including bone mineral density.¹¹

The fracture risk is not static. It climbs with duration of use. A Dutch study specifically noted that the increased fracture risk among SSRI users further increased with prolonged use, and the authors warned that physicians prescribing SSRIs to older patients should be aware of this unfavorable long-term consequence.¹² If you are taking citalopram long-term, especially if you are postmenopausal or have other risk factors for osteoporosis, periodic bone density screening is worth discussing with your doctor.

Heart Rhythm Changes

Citalopram can lengthen the QT interval on an electrocardiogram, a measure of how long the heart takes to reset between beats. A prolonged QT interval is not something you would feel directly, but in rare cases it can trigger dangerous heart rhythms. This effect is dose-dependent: higher doses carry more risk.¹³ The concern was significant enough that the FDA capped the recommended maximum dose of citalopram at 40 mg per day in 2011, and at 20 mg per day for adults over 60.

Research confirms that cardiac safety concerns remain real at doses above the recommended ceiling.¹⁴ Even at therapeutic doses, citalopram has been associated with QT prolongation.¹⁵ For most people with a healthy heart, the effect is clinically insignificant. But if you take other medications that also prolong the QT interval, or if you have a personal or family history of cardiac arrhythmias, low potassium, or low magnesium, the risk compounds. Your prescriber may order a baseline ECG and periodic follow-ups, particularly if you are on a higher dose or have other risk factors.

Bleeding Risk

Serotonin plays an important role in blood clotting. Platelets use serotonin transporters to stockpile serotonin, which they release when you are injured to help form a clot. Citalopram blocks that transporter, depleting serotonin from platelet storage and impairing aggregation. The clinical result is a modestly increased tendency to bleed, particularly in the gastrointestinal tract and, more rarely, intracranially.¹⁶ SSRIs can also increase gastric acid secretion, raising the risk of stomach ulcers, which further compounds the GI bleeding issue.

This becomes especially relevant if you also take blood thinners, aspirin, or non-steroidal anti-inflammatory drugs like ibuprofen. The combination magnifies the bleeding risk considerably. If you are on long-term citalopram and need regular pain relief, it is worth talking to your doctor about alternatives that do not further impair clotting.

Low Sodium

Citalopram can occasionally cause your blood sodium to drop below normal, a condition called hyponatremia. It does this by triggering the inappropriate release of antidiuretic hormone, which causes the body to retain water and dilute the sodium in your blood. Mild cases may cause no symptoms at all, while moderate or severe cases can produce confusion, nausea, headaches, fatigue, and in extreme situations, seizures.

A retrospective study of patients newly prescribed citalopram found that the risk of developing hyponatremia was higher in older adults, in men, in those already taking thiazide diuretics, and in those who started with borderline-low sodium levels.¹⁷ Another report noted that the effect is more common in the elderly and in people with low body weight or pre-existing low sodium.¹⁸ If you have been on citalopram for a long time and experience persistent vague symptoms like fatigue or mental fogginess, a simple blood test for electrolytes can rule this out.

Cognitive Effects and Dementia

Whether SSRIs help or hurt cognition over the long haul is genuinely controversial. A review of the evidence noted that findings on cognitive impairment from SSRIs are “extremely controversial,” with some studies suggesting that SSRIs may actually improve cognition, while others point to subtle deficits.¹⁹ Part of the confusion comes from the difficulty of separating the cognitive effects of the drug from the cognitive effects of depression itself, which reliably impairs memory, concentration, and processing speed.

A national cohort study of patients with dementia found that those using citalopram showed faster cognitive decline compared to non-users.²⁰ A separate study looking at dementia risk over ten years found that citalopram users had a higher rate of dementia compared to users of some other antidepressants like fluoxetine and venlafaxine.²¹ These are observational findings, and it is very possible that the people prescribed citalopram differed from those prescribed other drugs in ways that matter. But for people already concerned about cognitive aging, the data is worth knowing about, especially if alternative antidepressants would work equally well for them.

Sleep Architecture

Citalopram alters the structure of your sleep even after your body has adjusted to the drug. Chronic treatment produces a sustained suppression of REM sleep, the phase associated with dreaming and memory processing, along with a shift toward lighter stages of slow-wave sleep.²² Some people on long-term citalopram report vivid dreams (often when they miss a dose and REM briefly rebounds), while others notice they feel less rested even after a full night of sleep. REM suppression is a class effect of SSRIs, not unique to citalopram, and its clinical significance for most people is unclear. But if you have persistent sleep complaints while taking citalopram, the drug’s effect on sleep architecture is one possible contributor.

Seizure Threshold

Among SSRIs, citalopram and paroxetine carry a relatively higher risk of lowering the seizure threshold compared to escitalopram and sertraline.²³ For most people without a history of seizures, this is unlikely to matter. But if you have epilepsy or another condition that puts you at risk for seizures, this relative difference between SSRIs is something your neurologist and psychiatrist should coordinate on.

Withdrawal Is Harder Than Many Prescribers Acknowledge

Getting off citalopram after long-term use can be surprisingly difficult. A meta-analysis estimated that roughly 46 percent of SSRI users experience withdrawal symptoms, and the rate climbs with treatment duration: about 35 percent for those who used the drug for six to twelve weeks, rising to over 50 percent for those who used it longer than 24 weeks.²⁴ The long-term user survey found that nearly three-quarters of respondents reported withdrawal effects, the single most commonly cited adverse outcome in the entire survey.²⁵

Symptoms can include dizziness, electric-shock sensations (often called “brain zaps”), irritability, insomnia, flu-like feelings, and a rebound of anxiety or depression that can be difficult to distinguish from a relapse. Standard clinical guidelines have traditionally recommended tapering over two to four weeks, but research shows these short tapers offer minimal benefit over stopping abruptly and are frequently not tolerated. A slower approach, tapering over months and reducing the dose gradually to levels well below the typical therapeutic minimum, has been shown to reduce withdrawal symptoms substantially.²⁶ The key insight is that the relationship between dose and brain effect is not linear: halving a dose from 20 mg to 10 mg cuts the drug’s effect on the serotonin transporter far less than halving from 5 mg to 2.5 mg. So the final, smallest dose reductions need to be the most gradual.

Your Genetics Influence Your Side-Effect Risk

Citalopram is processed primarily by a liver enzyme called CYP2C19, and people vary considerably in how active that enzyme is based on their genetics. If your CYP2C19 is slow, the drug lingers in your system at higher effective concentrations, raising the probability of side effects. A retrospective study found that for each step toward slower metabolism, the odds of drug intolerability dropped by about 27 percent for each step toward faster metabolism, meaning slower metabolizers experienced substantially more side effects, lower compliance, and more frequent treatment changes.²⁷

A large-scale analysis confirmed that slower CYP2C19 metabolizers taking citalopram were significantly more likely to report side effects and to discontinue treatment because of them. Roughly 26 percent of slower metabolizers stopped citalopram due to side effects compared to about 20 percent of faster metabolizers.²⁸ A separate Australian study of over 9,500 participants found that the pattern was clearest for sertraline but did not reach statistical significance for citalopram or escitalopram in that particular sample.²⁹ The overall picture across studies, though, strongly suggests that CYP2C19 status matters for citalopram tolerability. Pharmacogenomic testing is increasingly available and can help your prescriber choose a starting dose or consider a different SSRI if your genetics put you at higher risk for side effects.

Kidney and Liver Function

Citalopram is cleared mainly by the liver, so compromised liver function means the drug hangs around longer and at higher levels, amplifying every side effect discussed above. In people with severe chronic kidney disease, even though citalopram is not primarily eliminated by the kidneys, hepatic clearance of the drug was reduced by about 23 percent compared to those with moderate kidney disease.³⁰ This means kidney disease can indirectly slow citalopram clearance even though the kidneys are not the main route of elimination. Early clinical studies noted only transient, mild elevations in liver enzymes in a couple of patients.³¹ Serious liver injury from citalopram is rare, but if you already have liver disease or advanced kidney disease, dose reductions and closer monitoring are standard practice.

Citalopram During Pregnancy

Women who become pregnant while on citalopram face a difficult decision, and the data here is mixed in ways that do not resolve into a clean answer. A large Norwegian birth cohort study found that children prenatally exposed to citalopram or escitalopram were more likely to receive an ADHD diagnosis (about 7.5 percent) compared to unexposed controls (about 3 percent).³² However, children exposed to maternal depression alone also showed elevated ADHD rates, making it hard to know how much of the signal comes from the drug versus the underlying condition it treats.

A systematic review of prenatal antidepressant exposure and neurodevelopmental outcomes found that the majority of studies showed no difference between exposed and unexposed children, with only two studies identifying statistically significant differences in motor function.³³ Untreated severe depression during pregnancy carries its own risks, including preterm birth and low birth weight, so the decision to continue or stop citalopram during pregnancy involves weighing imperfect evidence on both sides. This is a conversation that belongs between you and your obstetrician and psychiatrist together, ideally before conception if the pregnancy is planned.

1
PubMed Central. Long-term antidepressant use: patient perspectives of benefits and adverse effects ↩︎
2
PubMed Central. Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs ↩︎
3
PubMed Central. Long-Term Citalopram Treatment Alters the Stress Responses of the Cortical Dopamine and Noradrenaline Systems: the Role of Cortical 5-HT 1A Receptors ↩︎
4
PubMed Central. Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies ↩︎
5
PubMed Central. Long-term antidepressant use: patient perspectives of benefits and adverse effects ↩︎
6
PubMed Central. Long-term antidepressant use: patient perspectives of benefits and adverse effects ↩︎
7
PubMed. Post-SSRI Sexual Dysfunction: A Literature Review ↩︎
8
PubMed Central. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants ↩︎
9
PubMed Central. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence ↩︎
10
PubMed. Antidepressant medications and osteoporosis ↩︎
11
PubMed Central. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS) ↩︎
12
Journal of Clinical Psychopharmacology. Selective Serotonin Reuptake Inhibiting Antidepressants Are Associated With an Increased Risk of Nonvertebral Fractures ↩︎
13
PubMed Central. Physical Side Effects of Psychoactive Meds: Evaluation of QTc prolongation and dosage effect with citalopram ↩︎
14
PubMed. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day ↩︎
15
Prescriber Update. Citalopram and Escitalopram – Similar Risk of QT Prolongation? ↩︎
16
PubMed Central. Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review ↩︎
17
PubMed Central. Factors Associated with Hyponatremia in Patients Newly Prescribed Citalopram: A Retrospective Observational Study ↩︎
18
PubMed Central. Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Induced by Long-Term Use of Citalopram and Short-Term Use of Naproxen ↩︎
19
PubMed Central. Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs ↩︎
20
PubMed Central. Antidepressant use and cognitive decline in patients with dementia ↩︎
21
PubMed. Analysis of the Effects of Selective Serotonin (and Noradrenaline) Reuptake Inhibitors on the Risk of Dementia in Patients with Depression ↩︎
22
PubMed. Citalopram: differential sleep/wake and EEG power spectrum effects after single dose and chronic administration ↩︎
23
Chonnam Medical Journal. Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review ↩︎
24
Nature. Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review ↩︎
25
PubMed Central. Long-term antidepressant use: patient perspectives of benefits and adverse effects ↩︎
26
The Lancet Psychiatry. Tapering of SSRI treatment to facilitate discontinuation ↩︎
27
PubMed Central. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study ↩︎
28
medRxiv. Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects ↩︎
29
The Pharmacogenomics Journal. Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study ↩︎
30
EMJ Nephrology. Impact of Chronic Kidney Disease on the Drugs Eliminated Predominantly Through a Non-Renal Route: A Proof of Concept Study with Citalopram ↩︎
31
PubMed. Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect–a phase II study ↩︎
32
Translational Psychiatry. Effects of prenatal exposure to (es)citalopram and maternal depression during pregnancy on DNA methylation and child neurodevelopment ↩︎
33
PubMed. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review ↩︎